{
    "url_original": "https://www.wsj.com/articles/pill-intended-to-be-covid-19s-tamiflu-succeeds-in-key-study-11633082401?mod=business_lead_pos1",
    "url": "pill-intended-to-be-covid-19s-tamiflu-succeeds-in-key-study-11633082401",
    "title": "Pill Intended to Be Covid-19’s Tamiflu Succeeds in Key Study",
    "sub_head": "Drug from Merck and Ridgeback Biotherapeutics cut risk of hospitalization or death by 50% in early look at progress",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-409950?width=860&height=573",
    "image_1": "im-409950.jpg",
    "time": "2021-10-01 06:00:00",
    "body": "Merck  & Co. and its partner Ridgeback Biotherapeutics LP said their experimental Covid-19 pill helped prevent high-risk people early in the course of the disease in a pivotal study from becoming seriously ill and dying, a big step toward providing the pandemic’s first easy-to-use, at-home treatment.<br />The pill cut the risk of hospitalization or death in study subjects with mild to moderate Covid-19 by about 50%, the companies said Friday."
}